Thrombopoietin (TPO), the ligand for the receptor protooncogene c-mpl, has been cloned and shown to be the critical regulator of platelet production. Several features of c-Mpl expression, including its presence on erythroid cell lines, and the panmyeloid transformation characteristic of myeloproliferative leukemia (MPL) viral disease led us to investigate whether this receptor-ligand system may play a role in erythropoiesis. We report that although TPO alone did not support the growth of either early or late erythroid progenitors, it acted in synergy with erythropoietin to expand these populations. Moreover, while the effects on erythropoiesis in normal animals were modest, TPO greatly expanded the number of erythroid progenitors and blood reticulocytes and was associated with accelerated red cell recovery in myelosuppressed mice. Together, these data strongly suggest that erythroid progenitors respond to TPO and that this newly cloned cytokine, critical for platelet production, can augment erythropoiesis in states of marrow failure. (J. Clin. Invest. 1995. 96:1683-1687
Introduction
Recently, we and others have cloned the ligand for the c-Mpl receptor (1) (2) (3) (4) . In subsequent studies it was shown that the Mpl ligand supports the proliferation of megakaryocytic progenitors and their differentiation into large polyploid, platelet-producing megakaryocytes (5, 6) . Moreover, Mpl ligand levels are inversely related to platelet count, and the administration of the cytokine profoundly drives platelet production in normal animals (5, 6) . On these grounds, we proposed that Mpl ligand 1 . Abbreviations used in this paper: BHK, baby hamster kidney; EPO, erythropoietin; KL, c-kit ligand; PWM-SCM, pokeweed mitogen spleen cell-conditioned medium; rm, recombinant murine; RBC, red blood cell; TPO, thrombopoietin. is identical to thrombopoietin (TPO),1 the critical regulator of thrombopoiesis (7, 8) . A more recent study in which Mpl receptor expression was eliminated by homologous recombination in genetically engineered mice (9) substantiates this conclusion.
The regulation of red blood cell (RBC) development is one of the critical homeostatic mechanisms of higher organisms. Over the past several years, many of the humoral regulators of erythropoiesis have been identified and molecularly cloned. Although IL-3 (10, 11), GM-CSF (12, 13) , and c-kit ligand (KL [14] ) have been shown to expand early erythroid progenitors, erythropoietin (Epo), which promotes the terminal differentiation of these cells, is thought to be the critical regulator of red cell production ( 15, 16) .
In recent years, multiple lines of evidence point to a common origin of the erythroid and megakaryocytic lineages (for review see reference 17). For example, erythroleukemic cell lines express markers of megakaryocytic differentiation (18) (19) (20) , and erythroid and megakaryocytic cells display a number of common surface markers and transcription factors (21, 22) . Furthermore, several groups have shown that Epo augments the effects of plasma TPO on megakaryocyte formation in vitro, although the platelet response to its in vivo administration to normal animals has been variable (23) (24) (25) . To determine the effects of TPO on erythropoiesis we evaluated the effects of this new cytokine on in vitro and in vivo red cell production, using both normal mice and those rendered pancytopenic with myelosuppressive therapy. We report that in Epo-containing cultures, TPO enhances the development of early erythroid progenitors and the generation of late erythroid colony-forming cells. In vivo, after cytoreductive therapy, TPO speeds the repopulation of the marrow and spleen with both early and late erythroid precursors, resulting in enhanced red cell production and earlier erythrocyte recovery. These results strongly support the hypothesis that erythroid and megakaryocyte progenitors respond to overlapping signals and suggest that the clinical utility of thrombopoietin may be greater than initially anticipated.
Methods
In vivo studies. 8-12-wk-old female Balb/c mice (The Jackson Laboratories, Bar Harbor, ME) were maintained in a controlled American Association for Laboratory Animal Care-certified animal care facility and provided water and standard laboratory chow ad lib. All procedures were approved by the University of Washington and ZymoGenetics Animal Care Committees. For studies in normal mice, groups of five animals were administered recombinant murine (rm) TPO intraperitoneally once daily and killed on day 7. Additional groups of five mice were exposed to 350 cGy total body irradiation from a 137CS source (Gammacell 40 Irradiator; Atomic Energy of Canada Radiochemical Co., Kanata, Canada) followed by a single intraperitoneal injection of 1.2 mg carboplatinum, adapting a previously described model (26 (27) . Megakaryocytic progenitor cell numbers were determined as previously described (5) . Marrow cells were obtained by flushing both femurs into CATCH medium (0.38% sodium citrate, 2 x 10-3 M theophylline, 1 x 10-3 M adenosine in HBSS) and were plated at 2 x 105 per ml in Iscove's modified Dulbecco's medium supplemented with 15% preselected horse serum, antibiotics, 600 U/ml murine IL-3, and 1,000 U/ml murine TPO and were made semisolid with 0.275% agar. Cultures were incubated in a fully humidified 5% C02-containing atmosphere, and megakaryocyte colonies (containing 2 3 cells) were enumerated by inverted microscopy on day 5.
Recombinant TPO. The rmTPO used for in vivo studies was expressed in mammalian cells and assayed as previously described (1). Conditioned media were collected and concentrated by ultrafiltration. An affinity column was constructed by coupling murine Mpl receptor to CNBr Sepharose and was used to purify rmTPO. After buffer exchange to 20 mM Tris/ 1 mM EDTA, the protein was loaded onto the column and eluted with 3 M KSCN. Fractions containing material absorbing at A280 were pooled and dialyzed into 20 mM Tris (pH 8).
The final material consisted of a mixture of TPO molecular weight forms with the 70-and 30-kD forms most prominent. Doses are expressed as units, where 50 U are defined as the amount of rmTPO stimulating a half-maximal response in the BaF3/mouse mpl mitogenesis assay (1, 5) . For in vitro experiments, serum-free culture medium conditioned by BHK cells engineered to express the full length form of rmTPO was used at appropriate dilution. Control experiments contained a similar dilution of sham-transfected BHK cell serum-free culture medium. In three in vitro experiments, highly purified rmTPO was used.
Statistics. Significant differences between paired results were determined by the Mann-Whitney test.
Results and Discussion
In initial studies, normal mice were treated for 7 d with either vehicle or rmTPO, and their hematologic parameters were moni- Marrow and spleen cells were also tested for the number of early (BFU-E) and late (CFU-E) erythroid precursors under optimal culture conditions. Compared to mice treated with vehicle alone, BFU-E were significantly expanded in the marrow and CFU-E redistributed from the marrow to the spleens of TPO-treated animals. As indicated by the increased reticulocyte counts in the TPO-treated mice, these changes in erythroid progenitors were associated with a minor increase in the rate of red cell production (Table I) . Despite these changes, however, RBC levels in the TPO-treated animals failed to rise. The modest effect of TPO on erythropoiesis in our experiments with normal animals may have been due to the short duration of exposure, the low levels of other cytokines critical for erythroid development, or the action of counterregulatory mechanisms which temper responsiveness. This latter mechanism was invoked to explain the differences between the effects of IL-3 on neutrophil production in normal and pancytopenic primates (29) . As part of a study to establish the effectiveness of TPO in thrombocytopenic animals and to determine if its effects on erythropoiesis might be more pronounced if potential restraints on erythropoiesis were eliminated, we administered TPO to myelosuppressed mice. The effects of TPO on megakaryocytic progenitors and platelet recovery were marked and will be reported elsewhere (Grossmann, A., J. Lenox, J. M. Humes, H. P. Ren, J. W. Forstrom, K. Kaushansky, and K. H. Sprugel, manuscript submitted for publication). In addition, compared to animals receiving vehicle alone, the magnitude of the drop in red blood cell levels was significantly reduced, and recovery was accelerated (Fig. 1) . Nadir red blood cell counts were 41% of normal in vehicle-treated animals compared to 80% of normal Figure 1 . TPO improves red cell recovery after myelosuppressive therapy. 8-wk-old female Balb/c mice were given a sublethal dose of total body irradiation followed by a single intraperitoneal injection of carboplatinum on day 0. Red cell and reticulocyte levels were measured on samples collected by retroorbital bleeding before myelosuppression and at the indicated days after irradiation. The data represent the mean±SEM red blood cell counts of five mice treated with vehicle ( ) or five mice treated with 50 kU rmTPO (---E--- in TPO-treated mice. In these animals, no macroscopic or microscopic signs of bleeding were noted. Moreover, red cell production in the TPO-treated animals was enhanced, manifest by increased reticulocyte counts during the recovery period.
To further investigate the mechanism of the protective effects of TPO on red cell levels after myelosuppressive therapy, we performed additional experiments in which multiple erythropoietic parameters were monitored throughout the recovery period. Mice were treated with radiation and carboplatinum and BFU-E -4 (x1O CFU-E -6) (xlO then administered either rmTPO or vehicle for 12 d and killed on day 13. Although microscopic bleeding was noted on the surface of the brain and at an occasional site in some of the vehicle-treated animals in this particular experiment that was not detected in the TPO-treated mice, the latter group also displayed profound changes in red cell production (Fig. 2) . The mechanism of increased erythrocyte production was an expansion of marrow and splenic erythroid precursors. Although hematopoietic progenitors of all types were barely detectable in the myelosuppressed vehicle-treated animals, in myelosuppressed TPO-treated mice early erythroid progenitors had recovered to 20% of the level present in normal animals, late erythroid progenitors had recovered to 60%, and blood reticulocyte levels had recovered to those found in normal animals. These changes Marrow Spleen Total Marrow Spleen Total Blood Figure 2 . TPO hastens erythroid progenitor recovery after myelosuppressive therapy. Balb/c mice were treated with radiation and carboplatinum (as described in Fig. 1 ) and then with either vehicle (0) or 40 kU/d rmTPO (m) given subcutaneously twice daily for 12 d. Midway through the platelet recovery phase (day 13) the animals were killed and marrow and spleen obtained and assayed for all early and late erythroid progenitors. The results represent the mean progenitor numbers (±SEM) of five animals in each group. The reported progenitor numbers are for the entire marrow, assuming that one femur represents 6% of the total marrow-bearing space (30) . The total number of progenitors is the sum of those present in the marrow and spleen. In contrast to erythroid progenitor levels of 10-65% of normal values in myelosuppressed, TPO-treated animals, virtually no erythroid progenitors were detected in the myelosuppressed, vehicle-treated mice. Similar results were obtained in two additional experiments in C57B 1/6 mice given once-daily doses of vehicle or rmTPO. Figure 3 . TPO augments the size and number of erythroid bursts in response to IL-3 or KL and Epo. Early erythroid progenitors (BFU-E) were assayed as described in Methods using purified cytokines instead of PWM-SCM. All cultures contained 2 U/ml recombinant human Epo, added on day 3. Cultures containing 80 or 800 U/ml rmIL-3, 2 or 50 ng/ml rmKL, sham BHK-conditioned medium or 400 U/ml rmTPO are Day of Culture Figure 4 . TPO enhances the generation of CFU-E in suspension culture.
A two-stage culture system was used to assess the influence of rmTPO (Fig. 3) . In addition, when marrow cells were placed in suspension culture in the presence of TPO plus Epo, the number of output CFU-E was substantially greater than in the presence of Epo alone (Fig. 4) (10-14, 33, 34) , including effects on erythropoietic progenitors in vivo (35) (36) (37) (38) (39) (40) , late-acting cytokines, including Epo, G-CSF, M-CSF, IL-5, and TPO were initially thought to be lineage-specific (7, 8, 15, 16, 41, 42) . However, more recent findings suggest that many of these cytokines may also affect other cell lineages. For example, G-CSF has been shown to act in synergy with IL-3 or KL to trigger very early hematopoietic progenitors into the cell cycle, and M-CSF affects placental development and osteoid cells (43) (44) (45) . Of considerable interest for the present studies, Epo has been shown to augment megakaryocyte formation in the presence of aplastic serum, a known source of TPO (23, 24) , and to expand not only erythroid but also megakaryocyte and granulocytic progenitors in Epo-treated patients (46) . Therefore, our results have both physiologic and therapeutic implications. First, recognition of the interaction between TPO and erythropoiesis adds to our growing appreciation of the considerable pleiotropy exhibited by hematopoietic cytokines (47) . Second, as TPO influences multiple hematopoietic progenitors in the proper environment, elevated levels of the cytokine can impact the development of other blood cell types. These findings suggest that the therapeutic use of TPO in iatrogenic and natural states of marrow failure may be greater than initially anticipated.
